Drug Search Results
Using advanced filters...
Advanced Search [+]

Doxepin

Alternative Names: doxepin, mf 10, zonalon, silenor, sinequan, prudoxin
Clinical Status: Inactive
Latest Update: 2025-06-09
Latest Update Note: News Article

Product Description

Doxepin is used to treat anxiety or depression. It is also used to treat insomnia (trouble with sleeping). Doxepin is a tricyclic antidepressant (TCA). It works on the central nervous system (CNS) to increase levels of certain chemicals in the brain. This medicine is available only with your doctor's prescription.

Mechanisms of Action: SNR Inhibitor,H1 Antagonist,MR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Canada | Chile | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | New Zealand | Norway | Pakistan | Poland | Portugal | Romania | Slovenia | South Africa | Spain | Sri Lanka | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Currax Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doxepin

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Insomnia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20250406

P1

Completed

Insomnia

2025-01-23

2025-06-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status